BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 30282869)

  • 1. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
    J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
    Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
    Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM.
    Takato H; Waseda Y; Watanabe S; Inuzuka K; Katayama N; Ichikawa Y; Yasui M; Fujimura M
    Respir Med; 2013 Jan; 107(1):128-33. PubMed ID: 23137883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
    Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T
    PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.
    Wakura R; Matsuda S; Kotani T; Shoda T; Takeuchi T
    Sci Rep; 2020 Sep; 10(1):15692. PubMed ID: 32973255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study.
    Nakazawa M; Kaneko Y; Takeuchi T
    Clin Rheumatol; 2018 Mar; 37(3):765-771. PubMed ID: 28975463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-BĂ©jui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
    Hozumi H; Fujisawa T; Nakashima R; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.
    Isoda K; Kotani T; Takeuchi T; Kiboshi T; Hata K; Ishida T; Otani K; Kamimori T; Fujiwara H; Shoda T; Makino S
    Rheumatol Int; 2017 Aug; 37(8):1335-1340. PubMed ID: 28451794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
    Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
    Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
    Gono T; Tanino Y; Nishikawa A; Kawamata T; Hirai K; Okazaki Y; Shibata Y; Kuwana M
    Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.